NEW YORK, Jan 8, 2026, 08:59 (EST) — Premarket
Omeros Corp (OMER.O) shares were up 0.55, or about 4%, at $14.09 in premarket trade on Thursday after the drugmaker set a $36,000 price for each single-dose vial of its newly approved Yartemlea treatment for transplant-associated thrombotic microangiopathy (TA-TMA). “Median utilization was 8 to 10 vials per treatment course,” Chief Executive Gregory Demopulos told analysts. The stock rose 6.6% in extended trade on Wednesday. Reuters
The pricing matters because Omeros is trying to turn a long-running development story into a launch, with Yartemlea (narsoplimab-wuug) positioned as the first and only approved inhibitor of the lectin pathway of complement — part of the immune system — for TA-TMA, the company said. Omeros said it kicked off the U.S. market launch on Jan. 2 and that a European Medicines Agency review is underway, with a decision expected in mid-2026. It estimates about 30,000 allogeneic, or donor-cell, transplants are performed each year in the United States and Europe, and recent studies put TA-TMA incidence as high as 56% in those patients.
A filing showed Omeros had about $171.5 million of cash and short-term investments available for operations at Dec. 31, a preliminary, unaudited figure it disclosed in prepared remarks for Wednesday’s investor call. For small-cap biotechs, cash often drives the next question: whether the launch funds the pipeline, or the company has to raise again.
At $36,000 a vial, an eight-to-10-vial course implies a list-price bill of roughly $288,000 to $360,000 before rebates and discounts. That math puts reimbursement front and center, and it leaves little room for a slow start.
Brokerage calls followed the pricing and launch update. H.C. Wainwright analyst Brandon Folkes lifted his price target to $40 from $20 and kept a Buy rating, while D. Boral Capital’s Jason Kolbert reiterated a Buy and a $36 target, Benzinga data showed.
The stock’s 52-week range is $2.95 to $17.65. Traders have been watching the $13.50 area near the prior close and the $15 level after the stock’s recent $15.12 intraday high.
But high-price orphan launches can misfire. If insurers push back on dosing, limit coverage, or require extra paperwork at transplant centers, the revenue ramp can stretch out — and that brings cash burn and financing risk back into the frame.
